Glenmark Pharma launches Methylene Blue injection in USA
Glenmark Pharmaceuticals launched Methylene Blue Injection USP, 50 mg/10 mL in the US market. The product is indicated for the treatment of acquired methemoglobinemia. Launch expands Glenmark’s presence in the US generics segment. 📊 STOCKS: GLENMARK | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Launch
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.